This inventor holds 3 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Mink Therapeutics, Inc.. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2025
Sure, here is the article you requested:
Title: Spotlight on Inventor Sébastien Lalevée
Introduction:
Inventor Sébastien Lalevée, based in Saint Louis, France, has made significant contributions to the field with a total of 2 patents under his belt.
Latest Patents:
Sébastien Lalevée's latest patents include groundbreaking developments in T cell receptors, specifically focusing on binding to mixed lineage leukemia (MLL)-specific phosphopeptides and NY-ESO-1. These patents introduce innovative methods for treating subjects using TCRs that target these specific components.
Career Highlights:
Sébastien Lalevée is affiliated with Mink Therapeutics, Inc., where he plays a pivotal role in research and innovation. His dedication to advancing T cell receptor technology showcases his commitment to pushing the boundaries of medical science.
Collaborations:
Throughout his career, Sébastien Lalevée has collaborated closely with esteemed colleagues such as Marc VAN DIJK and Arthur Andrew Hurwitz. These collaborations have resulted in fruitful partnerships that have furthered the progress of his inventions.
Conclusion:
In conclusion, Sébastien Lalevée's work in the realm of T cell receptor technology stands as a testament to his ingenuity and passion for advancing medical treatments. His patents reflect a deep understanding of molecular science and a drive to make a positive impact on healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile